• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A letter to editor - Critical appraisal on "Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France.".

作者信息

Schwarze Juan-Enrique, Chaudhari Vivek, Montenegro Susana, Castello-Bridoux Claire, Masseria Cristina, Roeder Claudia

机构信息

Merck Healthcare, Merck KGaA, Darmstadt, Germany.

EMD Serono Inc., Rockland, MA, USA.

出版信息

Eur J Obstet Gynecol Reprod Biol X. 2024 Aug 2;23:100332. doi: 10.1016/j.eurox.2024.100332. eCollection 2024 Sep.

DOI:10.1016/j.eurox.2024.100332
PMID:39220094
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11364125/
Abstract
摘要

相似文献

1
A letter to editor - Critical appraisal on "Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France.".致编辑的一封信——对“在法国接受生育治疗的女性中，评估重组人促卵泡激素α生物类似药与重组人促卵泡激素α原研药的成本效益”的批判性评价
Eur J Obstet Gynecol Reprod Biol X. 2024 Aug 2;23:100332. doi: 10.1016/j.eurox.2024.100332. eCollection 2024 Sep.
2
Reply to Letter to Editor from Juan-Enrique Schwarze and colleagues - Critical appraisal on "Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France".对胡安 - 恩里克·施瓦泽及其同事致编辑信的回复——对“确定在法国接受生育治疗的女性中，与重组人促卵泡素α原研药相比，重组人促卵泡素α生物类似药的成本效益”的批判性评价
Eur J Obstet Gynecol Reprod Biol X. 2024 Aug 2;23:100331. doi: 10.1016/j.eurox.2024.100331. eCollection 2024 Sep.
3
Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France.确定在法国接受生育治疗的女性中，与重组人促卵泡素α原研药相比，重组人促卵泡素α生物类似药的成本效益。
Eur J Obstet Gynecol Reprod Biol X. 2024 May 3;22:100311. doi: 10.1016/j.eurox.2024.100311. eCollection 2024 Jun.
4
A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility.一项比较原研促卵泡素α与生物类似药治疗不孕症的成本效益评估。
Int J Womens Health. 2016 Dec 7;8:683-689. doi: 10.2147/IJWH.S118687. eCollection 2016.
5
A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany.德国促卵泡素α原研药与生物类似药用于辅助生殖的成本效益评估。
Int J Womens Health. 2019 May 13;11:319-331. doi: 10.2147/IJWH.S193048. eCollection 2019.
6
Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: A cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers.西班牙原创重组人促卵泡素α与重组人生长激素促卵泡素α生物类似药的比较：与新鲜胚胎移植相关的辅助生殖技术的成本效益分析
Best Pract Res Clin Obstet Gynaecol. 2022 Dec;85(Pt B):203-216. doi: 10.1016/j.bpobgyn.2022.01.011. Epub 2022 Feb 8.
7
Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study.在真实世界临床实践中接受原研促卵泡素α和促卵泡素α生物类似药治疗的患者的临床结局：一项回顾性研究
J Hum Reprod Sci. 2023 Apr-Jun;16(2):148-155. doi: 10.4103/jhrs.jhrs_37_23. Epub 2023 Jun 30.
8
A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain.一项成本效益模型评估，比较了一种生物类似物重组人促卵泡素α制剂与其参比产品在德国、意大利和西班牙实现活产结局的情况。
J Med Econ. 2018 Nov;21(11):1096-1101. doi: 10.1080/13696998.2018.1511567. Epub 2018 Aug 31.
9
A large observational data study supporting the PROsPeR score classification in poor ovarian responders according to live birth outcome.一项支持 PROsPeR 评分分类的大型观察性数据研究，该分类依据活产结局对卵巢低反应患者进行分类。
Hum Reprod. 2021 May 17;36(6):1600-1610. doi: 10.1093/humrep/deab050.
10
Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis.生物类似重组促卵泡素阿尔法制剂与参照产品（果纳芬®）在接受辅助生殖技术治疗的夫妇中的比较：系统评价和荟萃分析。
Reprod Biol Endocrinol. 2021 Apr 2;19(1):51. doi: 10.1186/s12958-021-00727-y.

本文引用的文献

1
Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France.确定在法国接受生育治疗的女性中，与重组人促卵泡素α原研药相比，重组人促卵泡素α生物类似药的成本效益。
Eur J Obstet Gynecol Reprod Biol X. 2024 May 3;22:100311. doi: 10.1016/j.eurox.2024.100311. eCollection 2024 Jun.
2
Letter to the editor in response to 'A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose' by P. Barrière, S. Hamamah, E. Arbo, C. Avril, B. Salle, J.-L. Pouly, et al. (J Gynecol Obstet Hum Reprod. 2023;52(1):102510).
J Gynecol Obstet Hum Reprod. 2023 Oct;52(8):102640. doi: 10.1016/j.jogoh.2023.102640. Epub 2023 Aug 6.
3
Comparative effectiveness of gonadotropins used for ovarian stimulation during assisted reproductive technologies (ART) in France: A real-world observational study from the French nationwide claims database (SNDS).法国辅助生殖技术（ART）中促性腺激素用于卵巢刺激的疗效比较：来自法国全国索赔数据库（SNDS）的真实世界观察性研究。
Best Pract Res Clin Obstet Gynaecol. 2023 Jun;88:102308. doi: 10.1016/j.bpobgyn.2022.102308. Epub 2022 Dec 28.
4
A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose.一项在法国开展的关于辅助生殖技术（ART）的真实世界研究（REOLA），根据重组促卵泡激素（rFSH）起始剂量，将一种生物类似药rFSH与原研药进行比较。
J Gynecol Obstet Hum Reprod. 2023 Jan;52(1):102510. doi: 10.1016/j.jogoh.2022.102510. Epub 2022 Nov 17.
5
Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1.模型化良好的研究实践概述：ISPOR-SMDM 模型化良好的研究实践工作组的报告——1.
Value Health. 2012 Sep-Oct;15(6):796-803. doi: 10.1016/j.jval.2012.06.012.